GBL-Containing Supplements Should Be Recalled - FDA "Talk Paper"
This article was originally published in The Tan Sheet
Executive Summary
FDA will proceed with regulatory action, such as a warning letter, against gamma butyrolactone (GBL) dietary supplement producers if they do not respond to an agency request for the companies to voluntarily recall their products. The agency suggested the voluntary recall in a Jan. 21 "Talk Paper."